Global Rechargeable Spinal Cord Stimulator (SCS) Systems Market, By Application (Failed Back Surgery Syndrome, Complex Regional Pain Syndrome, Ischemic Limb pain, and Others), End Use (Hospitals & Clinics and Ambulatory Facilities) – Industry Trends and Forecast to 2031.
Rechargeable Spinal Cord Stimulator (SCS) Systems Market Analysis and Size
Chronic pain is a prevalent issue worldwide, affecting a significant portion of the population. Studies indicate that chronic pain affects at least 10% of the world's population, which is approximately 60 million people. In some countries and regions, the prevalence of chronic pain can be as high as 20-25. In addition, an estimated one in 10 people develop chronic pain every year globally. Chronic pain is a significant driver for the growth of the rechargeable spinal cord stimulator market.
Data Bridge Market Research analyses that the global rechargeable spinal cord stimulator (SCS) systems market which was USD 1138.2 million in 2023, would rocket up to USD 1746.78 million by 2031, and is expected to undergo a CAGR of 5.50% during the forecast period. This indicates the market value. “Failed Back Surgery Syndrome” dominates the application Segment of the Global Rechargeable Spinal Cord Stimulator (SCS) Systems market as it is a prevalent condition among patients who have undergone spinal surgeries, leading to persistent pain. This drives the demand for effective pain management solutions such as rechargeable spinal cord stimulators. Technological advancements in neuro modulation devices have improved the efficacy of spinal cord stimulation for managing chronic pain conditions, making FBSS a dominant application segment in the market. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016 - 2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Application (Failed Back Surgery Syndrome, Complex Regional Pain Syndrome, Ischemic Limb pain, and Others), End Use (Hospitals & Clinics, Ambulatory Facilities)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
A rechargeable spinal cord stimulator (SCS) is a medical device designed to alleviate chronic pain by delivering electrical impulses to the spinal cord, providing pain relief through neuro modulation; unlike traditional SCS devices, it incorporates a rechargeable battery system, offering longer-lasting use and greater flexibility in managing chronic pain conditions.
Rechargeable Spinal Cord Stimulator (SCS) Systems Market Dynamics
Drivers
- Extended Battery Longevity:
Advances in rechargeable battery technology contribute to longer-lasting power sources for spinal cord stimulators. Increased battery longevity enhances the convenience for patients, reducing the frequency of recharging procedures and promoting sustained pain management over extended periods. Increases adoption due to the assurance of longer-lasting battery performance, making rechargeable systems more attractive. These features enhance patient outcomes, reduce healthcare costs, and increase the adoption of rechargeable SCS technology.
- Improved Programmability:
Continuous innovation allows for greater flexibility and customization in programming rechargeable spinal cord stimulators. Improved programmability enables healthcare professionals to tailor treatment parameters more precisely, optimizing pain relief for individual patients and expanding the applicability of these devices across a broader spectrum of chronic pain conditions. As technology advances in these areas, the market is poised for further growth, offering improved pain management solutions for individuals suffering from chronic pain conditions.
Opportunities
- Increasing Prevalence of Chronic Pain Conditions
The increasing prevalence of chronic pain disorders, such as failed back surgery syndrome and degenerative disc disease, is fostering a rising need for advanced pain management solutions. This trend positions the rechargeable segment to experience significant market expansion.
- Continuous Technological Advancements
The ongoing innovation in rechargeable spinal cord stimulators, characterized by extended battery life and enhanced programmability, represents a lucrative market prospect for increased adoption and growth. Continuous advancements in spinal cord stimulation (SCS) technology drive the growth of the rechargeable spinal cord stimulator market. Manufacturers are constantly developing innovative features such as smaller and more durable devices, improved electrode designs for better targeting of pain, and enhanced programming capabilities for personalized therapy. These technological innovations aim to improve the efficacy, comfort, and overall patient experience with rechargeable spinal cord stimulators, thereby increasing their adoption rates among patients suffering from chronic pain conditions.
Restraints/Challenges
- High Initial Expenditure
The initial cost of acquiring and implanting rechargeable spinal cord stimulators is relatively high, limiting access for some patients and healthcare systems.
Affordability issues may hinder widespread adoption, especially in regions with limited healthcare resources or for individuals without comprehensive insurance coverage.
- Invasive Nature and Risks
The surgical implantation of rechargeable spinal cord stimulators involves an invasive procedure carrying inherent risks such as infection, bleeding, or device-related complications. Concerns about the invasive nature and potential complications may deter both patients and healthcare providers from opting for this treatment, impacting the overall market growth.
Recent Developments
- In December 2022, Abbott introduced the most compact implantable spinal cord stimulation system globally, featuring rechargeable capabilities designed to address chronic pain.
Rechargeable Spinal Cord Stimulator (SCS) Systems Market Scope
The global rechargeable spinal cord stimulator (SCS) systems market is segmented on the basis of application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
-
Failed Back Surgery Syndrome
-
Complex Regional Pain Syndrome
-
Ischemic Limb pain
-
Others
End User
- Hospitals
- Ambulatory Surgical Centers
- Clinics
Rechargeable Spinal Cord Stimulator (SCS) Market Regional Analysis/Insights
The global rechargeable spinal cord stimulator (SCS) systems market is analysed and market size insights and trends are provided by application, end use, and country as referenced above.
The countries covered in market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa.
North America is expected to dominate the market due to the substantial presence of key industry players such as Boston Scientific Corporation, Medtronic, Nevro, and others, contributing significantly to the region's market dominance.
Asia-Pacific is expected to witness significant growth due to the growing number of hospitals and rising healthcare spending.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Global Rechargeable Spinal Cord Stimulator Market the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the market.
Competitive Landscape and Rechargeable Spinal Cord Stimulator Market Share Analysis
The market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Medtronic ( Ireland)
- Abbott (U.S.)
- Boston Scientific (U.S.)
- Nevro Corp (U.S.)
- Nuvectra Corporation (U.S.)
- Stimwave LLC (U.S.)
- Saluda Medical (Australia)
- Axonics Modulation Technologies (U.S.)
- Integer Holdings Corporation (U.S.)
- Synapse Biomedical Inc. (U.S.)
SKU-